System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ppublish 2 citations

PubMed: 42716047 DOI: 10.1016/S1474-4422(26)00248-6

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.

Lancet Neurol 25(10):952-964

Authors: Jonathan Graff-Radford, Leah Karliner, Deborah E Barnes, Giovanni B Frisoni, Reisa Sperling, Nicolas Villain, Tammy L S Benzinger, Charlotte Teunissen, Clifford R Jack

Affiliations

  • Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Department of Psychiatry and Behavioral Sciences, and Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
  • Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva, Geneva, Switzerland.
  • Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Sorbonne Université, INSERM U1127, CNRS 7225, Institut du Cerveau-ICM, Paris, France; Department of Neurology, Institute of Memory and Alzheimer's Disease, AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France.
  • Department of Radiology, Washington University, St Louis, MO, USA.
  • Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, Netherlands.
  • Department of Radiology, Mayo Clinic, Rochester, MN, USA.

Abstract

The recent approval of disease-modifying therapies for symptomatic Alzheimer's disease is a major advance for a condition with few therapeutic options. Anti-amyloid monoclonal antibodies have shown clinically meaningful benefits in slowing cognitive decline. Clinical trials in symptomatic Alzheimer's disease suggest that anti-amyloid therapies might provide the greatest benefit in subgroups who have low baseline levels of Alzheimer's disease pathology; ongoing prevention trials are evaluating these therapies in cognitively unimpaired individuals who have biomarker evidence of Alzheimer's disease neuropathological change (ADNC). However, the possibility of biomarker testing and treatment in cognitively unimpaired people raises key questions about ethics and the consequences that follow from a positive test or an uncertain result (ie, the so-called downstream effects on patients and health systems). Furthermore, test accuracy might be questioned when ADNC has a low prevalence in the population being tested and in the case of intermediate-range biomarker concentrations that might not reliably indicate true ADNC or be false positives. If anti-amyloid therapies prove beneficial for cognitively unimpaired people with ADNC and become part of routine practice, several key knowledge gaps must be addressed to support safe, scalable, real-world implementation of Alzheimer's disease treatment.

MeSH

Alzheimer Disease, Biomarkers, Therapeutics, Amyloid, Nervous System